Company details are restricted to VIN members. Become a member to view company details.
Nob Hill Therapeutics, Inc. was formed to commercialize a first-in-kind dry powder nebulizer platform “DryNebTM” for respiratory inhalation drug delivery applications. The core proprietary technology of DryNebTM was invented at the University of New Mexico.
The Problem: Inhaled drug delivery enables targeted drug delivery directly to the infected pulmonary area and is characterized by its high bioavailability and fast action. The delivery method has been gaining importance as it greatly reduces the side effects/toxicity and improves therapy efficacy. However, current inhalation drug delivery devices (conventional nebulizer and dry powder inhaler) suffer from one or more of the following limitations: drug dilution, patient inhalation capability dependence, patient coordination needed, limitations for multi-drug delivery, specification to drug formulation, lack of ease of use, and more.
The Solution: Our patented DryNebTM technology solves both conventional nebulizer’s and dry powder inhaler’s major drawbacks. It uses a novel, yet simple, magnetically responsive element which results in much improved dry powder aerosol generation in the respirable range (1-5 µm). Also, it disperses the powder independently from the patient’s inhalation force, ensuring reproducible delivery no matter the lung function of the patient, and it is designed to emit powder from the device only when a patient inhales, thus no coordination required. It overcomes the limitations of currently available devices and provides a new delivery platform for inhalation drug delivery. Nob Hill is initially focusing on the lower respiratory infection treatment market.
Market Opportunity: In 2019, the inhalation therapeutics and inhaler-device markets were approximately $25B and $10B each, expected to expand at a CAGR of ~6 % and 3% respectively through 2025, with a combined market size of ~$50B. The lung infection treatment market has a great need for effective therapies through targeted drug delivery directly to the infection site, with only two indication treatments available on the market. Nob Hill has three market objectives: 1) Position DryNeb as the method/device of choice for dry powder inhalation drug delivery through partnerships; 2) Develop the first inhalation antifungal therapy using an already FDA approved drug, and 3) Build DryNeb’s therapy development pipeline. Each of these market objectives helps position the company as an acquisition target.